| P50 | author | Frank Balis | Q38641035 |
| P2093 | author name string | Balis FM | |
| P2860 | cites work | The fate of 6-mercaptopurine in man | Q78573330 |
| | Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion | Q93606585 |
| | Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice | Q93808471 |
| | Microsomal metabolism of nitrosoureas | Q28323092 |
| | Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans | Q28366957 |
| | Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice | Q28367498 |
| | Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside | Q33457201 |
| | Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy | Q34519074 |
| | Heparin does not modify plasma daunomycin disappearance in acute leukaemia patients | Q36044746 |
| | Cimetidine enhancement of cyclophosphamide antitumour activity | Q36046243 |
| | Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration | Q38537846 |
| | Bleomycin pharmacokinetics in man. I. Intravenous administration | Q38537946 |
| | A pH-dependent, carrier-mediated transport system for the folate analog, amethopterin, in rat jejunum | Q39172759 |
| | Combination chemotherapy--theory and practice | Q39625501 |
| | The clinical pharmacology of methotrexate.new applications of an old drug | Q39716312 |
| | Clinical Pharmacokinetics of Methotrexate1 | Q39720628 |
| | Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients | Q40026026 |
| | Methotrexate plasma decay kinetics: possible alteration in patients undergoing gut sterilization | Q40031175 |
| | Potentiation of chemotherapy by hypoxic cell radiation sensitizers--a review. | Q40336495 |
| | Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia | Q40484946 |
| | Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity | Q40655039 |
| | Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats | Q41441971 |
| | Decreased half life of cyclophosphamide in patients under continual treatment | Q41445391 |
| | Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid | Q41673533 |
| | Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen | Q42201490 |
| | Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration | Q42227440 |
| | Effect of pretreatment with phenobarbital or SKF 525A on the toxicity and antitumor activity of lomustine. | Q42258977 |
| | The influence of cimetidine on the pharmacokinetics of 5-fluorouracil | Q42531493 |
| | Enhancement of cisplatin nephrotoxicity by probenecid | Q42585034 |
| | Drug interactions and multiple drug administration | Q43525549 |
| | Inhibition of renal tubular transport of methotrexate by probenecid | Q43911534 |
| | Increased methotrexate toxicity due to concurrent probenecid administration | Q43953873 |
| | Drug interactions with antineoplastic agents | Q44021689 |
| | Prevention of renal failure in rats receiving cis-diamminedichloroplatinum(II) by administration of furosemide | Q46470785 |
| | Clinical pharmacology of cyclophosphamide | Q48012175 |
| | The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the pl | Q48112355 |
| | Prolongation and enhancement of serum methotrexate concentrations by probenecid | Q49901693 |
| | High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis | Q50622722 |
| | Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat. | Q51858085 |
| | Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. | Q52701227 |
| | High-dose cisplatin with sodium thiosulfate protection. | Q54121260 |
| | Plasma Protein Displacement Interactions Are Rarely of Clinical Significance | Q59488392 |
| | High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity | Q71545756 |
| | Inhibition of NADPH-cytochrome P450 reductase by cyclophosphamide and its metabolites | Q71550328 |
| | Test dose for predicting high-dose methotrexate infusions | Q71727462 |
| | Decreased plasma half-life of cyclophosphamide during repeated high-dose administration | Q71761531 |
| | Interaction of allopurinol with 6-mercaptopurine and azathioprine | Q71845825 |
| | Combination therapy with 6-mercaptopurine (NSC-755) and allopurinol (NSC-1390) during induction and maintenance of remission of acute leukemia in children | Q72358092 |
| | Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure | Q72624474 |
| | Enhanced bleomycin toxicity during acute renal failure | Q72658973 |
| | Cisplatin-induced changes in bleomycin elimination | Q72700824 |
| | Pharmacokinetics of Anticancer Drugs in Children | Q72720181 |
| | Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas | Q72755688 |
| | Nitroimidazoles as modifiers of nitrosourea pharmacokinetics | Q72825353 |
| | Interaction of probenecid with the protein binding of methotrexate. | Q64915838 |
| | Plasma half-life of cytosine arabinoside in patients with leukaemia--the effect of uridine | Q66842856 |
| | Clinical Pharmacokinetics of Cyclophosphamide | Q66897379 |
| | Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors | Q66931811 |
| | Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II) | Q66957072 |
| | Effect of probenecid on cerebrospinal fluid methotrexate kinetics | Q66958375 |
| | Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man | Q67040828 |
| | Analysis of cytidine deaminase and tetrahydrouridine interaction by use of ligand techniques | Q67247894 |
| | Binding of adriamycin to sulphated mucopolysaccharides | Q67262224 |
| | The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo | Q67284303 |
| | The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide | Q67438170 |
| | The synergistic effect of salicylates on methotrexate toxicity | Q67456426 |
| | Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model | Q67567829 |
| | Modification of the renal toxicity of cis-dichlorodiammineplatinum(II) with furosemide in male F344 rats | Q67585075 |
| | Drug interactions in clinical perspective | Q67653687 |
| | Alterations in adriamycin efficacy by phenobarbital | Q67784858 |
| | The effect of phenobarbital on cyclophosphamide antitumor activity | Q67796403 |
| | Effect of steroid hormone on activation of Endoxan (cyclophosphamide) | Q68734343 |
| | Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. Boston Collaborative Drug Surveillance Program | Q68772881 |
| | Plasma levels and urinary excretion of ( 14 C)cyclophosphamide and its radioactive metabolites in rats pretreated with prednisolone | Q69401192 |
| | Phenobarbital effects on cyclophosphamide pharmacokinetics in man | Q69461828 |
| | Effect of phenobarbital and SKF 525A on the toxicity, elimination and metabolism of cyclophosphamide in newborn mice | Q69480317 |
| | Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation | Q70043946 |
| | Clinical pharmacokinetics of intraarterial cisplatin in humans | Q70192268 |
| | Evaluation of bone marrow toxic reaction in patients treated with allopurinol | Q70209913 |
| | Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients | Q70386160 |
| | Enhancement of chemotherapy agents | Q70429114 |
| | Therapeutic efficacy of cyclophosphamide as a function of its metabolism | Q70453254 |
| | Interactions between cyclophosphamide and adriamycin metabolism in rats | Q70471806 |
| | The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate | Q70792552 |
| | Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid | Q70794486 |
| | Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats | Q70794499 |
| | Sodium thiosulfate inhibits cis-diamminedichloroplatinum (II) activity | Q70795601 |
| | Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum | Q70798183 |
| | Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol | Q70920774 |
| | Clinical pharmacology of l-β-D-arabinofuranosyl cytosine | Q71075171 |
| | Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial | Q71127527 |
| | The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol | Q71201433 |
| | The effect of organic acids on renal clearance of methotrexate in man | Q71232539 |
| | Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes | Q71263732 |
| | Antiheparin activity of Adriamycin | Q71317519 |
| | Effect of penicillin on the renal tubular secretion of methotrexate in the monkey | Q71321785 |
| | PLasma half-life and urinary excretion of cyclophosphamide in children | Q71470408 |
| | Drug interactions and the prepared observer | Q71488627 |
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 223-235 | |
| P577 | publication date | 1986-05-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Pharmacokinetic drug interactions of commonly used anticancer drugs | |
| P478 | volume | 11 | |